PT - JOURNAL ARTICLE AU - Estela Giménez AU - Eliseo Albert AU - Ignacio Torres AU - María José Remigia AU - María Jesús Alcaraz AU - María José Galindo AU - María Luisa Blasco AU - Carlos Solano AU - María José Forner AU - Josep Redón AU - Jaime Signes-Costa AU - David Navarro TI - SARS-CoV-2-reactive interferon-γ-producing CD8<sup>+</sup> T cells in patients hospitalized with Coronavirus viral disease-2019 AID - 10.1101/2020.05.18.20106245 DP - 2020 Jan 01 TA - medRxiv PG - 2020.05.18.20106245 4099 - http://medrxiv.org/content/early/2020/05/26/2020.05.18.20106245.short 4100 - http://medrxiv.org/content/early/2020/05/26/2020.05.18.20106245.full AB - There is limited information on SARS-CoV-2 T-cell immune responses in patients with Covid-19. Both CD4+ and CD8+ T cells may be instrumental in the resolution of and protection from SARS-CoV-2 infection. Here, we tested 25 hospitalized patients with either microbiologically documented Covid-19 (n=19) or highly suspected of having the disease (n=6) for the presence of SARS-CoV-2-reactive-CD69+-expressing interferon--producing-(IFN-) CD8+ T cells by a flow-cytometry for intracelular cytokine staining assay. Two sets of overlapping peptides encompassing the SARS-CoV-2 Spike glycoprotein N-terminal 1-643 amino acid sequence and the entire sequence of SARS-CoV-2 M protein were used simultaneously as antigenic stimulus. Ten patients (40%) had detectable responses, displaying frequencies ranging from 0.15 to 2.7% (median of 0.57 cells/μL; range, 0.43-9.98 cells/μL). The detection rate of SARS-CoV-2-reactive IFN-γ CD8+ T cells in patients admitted to intensive care was comparable (P=0.28) to that in patients hospitalized in other medical wards. No correlation was found between SARS-CoV-2-reactive IFN-γ CD8+ T-cell counts and SARS-CoV-2 S-specific antibody levels. Likewise, no correlation was observed between either SARS-CoV-2-reactive IFN-γ CD8+ T cells or S-specific IgG-antibody titers and blood cell count or levels of inflammatory biomarkers. In summary, in this descriptive, preliminary study we showed that SARS-CoV-2-reactive IFN-γ CD8+ T cells can be detected in a non-negligible percentage of patients with moderate to severe forms of Covid-19. Further studies are warranted to determine whether quantitation of these T-cell subsets may provide prognostic information on the clinical course of Covid-19.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo public or private funds were used for the current study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the corresponding author,(DN) upon reasonable request.